RHABDOID TUMOR
Clinical trials for RHABDOID TUMOR explained in plain language.
Never miss a new study
Get alerted when new RHABDOID TUMOR trials appear
Sign up with your email to follow new studies for RHABDOID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New stem cell approach aims to fight tough childhood cancers
Disease control Recruiting nowThis study tests a special stem cell transplant for children, teens, and young adults (ages 6 months to 25 years) with solid tumors that have come back or not responded to treatment. The transplant uses cells from a donor, with certain immune cells removed to reduce side effects,…
Matched conditions: RHABDOID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood cancers
Disease control Recruiting nowThis early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…
Matched conditions: RHABDOID TUMOR
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a cancer drug that blocks a key protein help kids with relapsed wilms tumor?
Disease control Recruiting nowThis phase II trial is testing the drug selinexor in people with Wilms tumor, rhabdoid tumor, MPNST, or other solid tumors that have returned or not responded to treatment. Selinexor works by blocking a protein called XPO1, which is often overactive in these cancers. The study ai…
Matched conditions: RHABDOID TUMOR
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Immunotherapy drug nivolumab takes on rare childhood cancer
Disease control Recruiting nowThis phase 2 trial is testing the immunotherapy drug nivolumab in 23 people aged 1 year and older with advanced or recurrent rhabdoid tumors that have not responded to chemotherapy. The goal is to see if the drug can shrink tumors and improve survival. Participants receive nivolu…
Matched conditions: RHABDOID TUMOR
Phase: PHASE2 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC